{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,9]],"date-time":"2026-08-09T00:43:21Z","timestamp":1786236201117,"version":"build-2736575974"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004070","name":"Khalifa University","doi-asserted-by":"publisher","award":["RC2-2018-022"],"award-info":[{"award-number":["RC2-2018-022"]}],"id":[{"id":"10.13039\/501100004070","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.ejphar.2026.179081","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T16:06:17Z","timestamp":1782230777000},"page":"179081","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["pH-responsive folate-targeted catalase conjugate for enhanced cellular uptake and oxidative stress protection in triple-negative breast cancer"],"prefix":"10.1016","volume":"1030","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-8678-4952","authenticated-orcid":false,"given":"Hamda","family":"Alfalasi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aya","family":"Shanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rouba D.","family":"Al Bostami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mzoun","family":"Alzaabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7382-2169","authenticated-orcid":false,"given":"Mary Krystelle","family":"Catacutan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae-Yeon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1699-8376","authenticated-orcid":false,"given":"Sungmun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2026.179081_bib1","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1186\/s12951-025-03364-4","article-title":"Tumor microenvironment-responsive precise delivery nanocarrier potentiating synchronous radionuclide therapy and chemotherapy against cancer","volume":"23","author":"An","year":"2025","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.ejphar.2026.179081_bib2","doi-asserted-by":"crossref","first-page":"9510","DOI":"10.1021\/acsanm.0c02234","article-title":"Optimization of gold nanoparticles for efficient delivery of catalase to macrophages for alleviating inflammation","volume":"3","author":"Ba Fakih","year":"2020","journal-title":"ACS Appl. Nano Mater."},{"key":"10.1016\/j.ejphar.2026.179081_bib3","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ejphar.2026.179081_bib4","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.3390\/molecules28031393","article-title":"Folic acid functionalized diallyl trisulfide\u2013solid lipid nanoparticles for targeting triple negative breast cancer","volume":"28","author":"De","year":"2023","journal-title":"Molecules"},{"key":"10.1016\/j.ejphar.2026.179081_bib5","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.3390\/pharmaceutics17101290","article-title":"Albumin nanoparticles in cancer therapeutics: clinical status, challenges, and future directions","volume":"17","author":"Kadri","year":"2025","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejphar.2026.179081_bib6","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.jddst.2019.05.033","article-title":"Human serum albumin: a nanomedicine platform targeting breast cancer cells","volume":"52","author":"Lee","year":"2019","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.ejphar.2026.179081_bib7","doi-asserted-by":"crossref","first-page":"9910","DOI":"10.3390\/ijms22189910","article-title":"Effect of exogenous pH on cell growth of breast cancer cells","volume":"22","author":"Lee","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2026.179081_bib8","article-title":"Reactive oxygen species-based nanomaterials for cancer therapy","volume":"9","author":"Li","year":"2021","journal-title":"Front. Chem."},{"key":"10.1016\/j.ejphar.2026.179081_bib9","article-title":"Triple-Negative breast cancer treatment advancements: a review of evolving strategies","volume":"2024","author":"Liu","year":"2024","journal-title":"Eur. J. Cancer Care"},{"key":"10.1016\/j.ejphar.2026.179081_bib10","doi-asserted-by":"crossref","DOI":"10.3390\/ijms251910712","article-title":"Solid lipid nanoparticles, an alternative for the treatment of triple-negative breast cancer","volume":"25","author":"Llaguno-Munive","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2026.179081_bib11","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1002\/ddr.21545","article-title":"Folic acid functionalized nanoparticles as pharmaceutical carriers in drug delivery systems","volume":"80","author":"Narmani","year":"2019","journal-title":"Drug Dev. Res."},{"key":"10.1016\/j.ejphar.2026.179081_bib12","doi-asserted-by":"crossref","first-page":"4742","DOI":"10.1021\/acsnano.9b01087","article-title":"Catalase-Integrated hyaluronic acid as nanocarriers for enhanced photodynamic therapy in solid tumor","volume":"13","author":"Phua","year":"2019","journal-title":"ACS Nano"},{"key":"10.1016\/j.ejphar.2026.179081_bib13","doi-asserted-by":"crossref","DOI":"10.1088\/0957-4484\/27\/18\/185704","article-title":"Optimization of anti-cancer drugs and a targeting molecule on multifunctional gold nanoparticles","volume":"27","author":"Rizk","year":"2016","journal-title":"Nanotechnology"},{"key":"10.1016\/j.ejphar.2026.179081_bib14","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ejphar.2026.179081_bib15","series-title":"Targeted Nanomedicine for Breast Cancer Therapy","first-page":"153","article-title":"Chapter 7 - folate receptor-mediated targeted breast cancer nanomedicine","author":"Varan","year":"2022"},{"key":"10.1016\/j.ejphar.2026.179081_bib16","doi-asserted-by":"crossref","first-page":"5675","DOI":"10.3390\/ijms25115675","article-title":"Antioxidant enzymes and their potential use in breast cancer treatment","volume":"25","author":"Vilchis-Landeros","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2026.179081_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.saa.2021.120477","article-title":"Fluorescein isothiocyanate-doped conjugated polymer nanoparticles for two-photon ratiometric fluorescent imaging of intracellular pH fluctuations","volume":"267","author":"Wang","year":"2022","journal-title":"Spectrochim. Acta Mol. Biomol. Spectrosc."},{"key":"10.1016\/j.ejphar.2026.179081_bib18","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1186\/s12951-022-01416-7","article-title":"All-in-one approaches for triple-negative breast cancer therapy: metal-phenolic nanoplatform for MR imaging-guided combinational therapy","volume":"20","author":"Xie","year":"2022","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.ejphar.2026.179081_bib19","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.addr.2012.09.041","article-title":"Targeting receptor-mediated endocytotic pathways with nanoparticles: rationale and advances","volume":"65","author":"Xu","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejphar.2026.179081_bib20","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/2112898","article-title":"Folate receptor-alpha targeted 7x19 CAR-\u03b3\u03b4T suppressed triple-negative breast cancer xenograft model in mice","volume":"2022","author":"Ye","year":"2022","journal-title":"J. Oncol."},{"key":"10.1016\/j.ejphar.2026.179081_bib21","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2023.1271420","article-title":"Advances in Doxorubicin-based nano-drug delivery system in triple negative breast cancer","volume":"11","author":"Zeng","year":"2023","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.ejphar.2026.179081_bib22","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.2147\/IJN.S360500","article-title":"pH-Responsive hyaluronic acid nanoparticles for enhanced triple negative breast cancer therapy","volume":"17","author":"Zeng","year":"2022","journal-title":"Int. J. Nanomed."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299926005637?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299926005637?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,9]],"date-time":"2026-08-09T00:32:26Z","timestamp":1786235546000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299926005637"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":22,"alternative-id":["S0014299926005637"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2026.179081","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"pH-responsive folate-targeted catalase conjugate for enhanced cellular uptake and oxidative stress protection in triple-negative breast cancer","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2026.179081","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"179081"}}